PDS Biotechnology Corp (EU6)

Currency in EUR
0.964
-0.008(-0.82%)
Closed·
EU6 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 12 days
Fair Value
Day's Range
0.9640.964
52 wk Range
0.8053.670
Key Statistics
Bid/Ask
0.925 / 0.941
Prev. Close
0.964
Open
0.964
Day's Range
0.964-0.964
52 wk Range
0.805-3.67
Volume
-
Average Volume (3m)
3.61K
1-Year Change
-69.34%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EU6 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

PDS Biotechnology Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

PDS Biotechnology Corp Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company’s lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. Further, the company provides PDS0202, a novel investigational influenza vaccine that protects against the strains predicted to be prevalent in an upcoming flu season. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.

Compare EU6 to Peers and Sector

Metrics to compare
EU6
Peers
Sector
Relationship
P/E Ratio
−1.4x−1.9x−0.5x
PEG Ratio
−0.04−0.070.00
Price/Book
2.3x0.9x2.6x
Price / LTM Sales
-64.9x3.2x
Upside (Analyst Target)
-297.7%43.8%
Fair Value Upside
Unlock10.6%8.1%Unlock

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.21 / -0.315
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

EU6 Income Statement

People Also Watch

136.73
ALAB
+6.10%
2.3300
LWLG
+0.43%
4.340
UNCY
-1.81%
17.190
QBTS
+0.76%
2.900
JSPR
-2.03%

FAQ

What Stock Exchange Does PDS Biotechnology Corp Trade On?

PDS Biotechnology Corp is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for PDS Biotechnology Corp?

The stock symbol for PDS Biotechnology Corp is "EU6."

What Is the PDS Biotechnology Corp Market Cap?

As of today, PDS Biotechnology Corp market cap is 42.83M.

What Is PDS Biotechnology Corp's Earnings Per Share (TTM)?

The PDS Biotechnology Corp EPS (TTM) is -0.94.

When Is the Next PDS Biotechnology Corp Earnings Date?

PDS Biotechnology Corp will release its next earnings report on 12 Aug 2025.

From a Technical Analysis Perspective, Is EU6 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has PDS Biotechnology Corp Stock Split?

PDS Biotechnology Corp has split 1 times.

How Many Employees Does PDS Biotechnology Corp Have?

PDS Biotechnology Corp has 24 employees.

What is the current trading status of PDS Biotechnology Corp (EU6)?

As of 01 Aug 2025, PDS Biotechnology Corp (EU6) is trading at a price of 0.96, with a previous close of 0.96. The stock has fluctuated within a day range of 0.96 to 0.96, while its 52-week range spans from 0.81 to 3.67.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.